Study of ATI-450 vs placebo in patients with moderate to severe psoriatic arthritis

illustrative image

The company Aclaris Therapeutics, Inc is commencing recruitment for the clinical trial of the Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis.

The trial officially began on the July 12, 2022 and is planned to complete on June 2023.

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05511519.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

Study of ATI-450 vs placebo in patients with moderate to severe psoriatic arthritis

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe